Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-10-09FDA Approved: ZELAPAR — Supplemental Application (Bausch Health US, LLC)
The FDA approved a supplemental application for Zelapar (selegiline hydrochloride) from Bausch Health US, LLC.
-
CLINICAL_TRIALS research · 2015-10-08Clinical Trial Update: Electromyography Signals as Biomarkers for Parkinson's Disease
A completed clinical trial evaluating electromyography signals as biomarkers for Parkinson's disease.
-
CLINICAL_TRIALS trial_result · 2015-10-06Clinical Trial Update: A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease [Phase 1]
A Phase 1 study evaluating AVE8112 in Parkinson's disease was terminated; the trial assessed safety, tolerability, pharmacokinetics, and pha…
-
CLINICAL_TRIALS research · 2015-10-05Clinical Trial Update: Fox Investigation for New Discovery of Biomarkers
A completed clinical trial update from the Michael J. Fox Foundation investigating new biomarkers for Parkinson's disease.
-
CLINICAL_TRIALS trial_result · 2015-10-02Clinical Trial Update: Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease [Phase 1]
Phase 1 clinical trial update evaluating efficacy, safety and tolerability of a Pfizer-sponsored treatment in Parkinson's disease; study sta…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-09-30Clinical Trial Update: Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease - Evolution
This clinical trial update confirms the completion of a study on orthostatic dysregulation and related gastrointestinal dysfunction in Parki…
-
CLINICAL_TRIALS research · 2015-09-29Clinical Trial Update: Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease [Phase 2]
A Phase 2 trial update examines whether transdermal nicotine could modify disease progression in early Parkinson's disease. The current stat…
-
FDA approval · 2015-09-28FDA Approved: ROPINIROLE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved Actavis Pharma, Inc.'s supplemental application for ropinirole, a generic ropinirole product.
-
FDA approval · 2015-09-24FDA Approved: CARBIDOPA AND LEVODOPA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Sun Pharmaceutical Industries’ carbidopa and levodopa product.
-
FDA approval · 2015-09-22FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's supplemental application for pramipexole dihydrochloride (Glenmark). The approval pertains to a generic version of t…
-
FDA approval · 2015-09-22FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for pramipexole dihydrochloride from Aurobindo Pharma Limited (ANDA 202633).
-
CLINICAL_TRIALS trial_result · 2015-09-18Clinical Trial Update: Psychoeducational Programme for PD Patients With STN-DBS [NA]
A clinical trial update indicates the study evaluating a psychoeducational programme for Parkinson's disease patients with deep brain stimul…
-
CLINICAL_TRIALS withdrawal · 2015-09-16Clinical Trial Update: Parkinson's Disease Genetics Database
A Northwell Health–sponsored clinical trial investigating a Parkinson's Disease genetics database was terminated.
-
CLINICAL_TRIALS trial_result · 2015-09-15Clinical Trial Update: Effects of Aerobic Exercise in Parkinson's Disease [NA]
A completed clinical trial studied the effects of aerobic exercise on patients with Parkinson disease; results were posted in 2015.
-
FDA approval · 2015-09-11FDA Approved: DATSCAN — Supplemental Application (Medi-Physics Inc. dba GE Healthcare.)
FDA approved a supplemental application for DATSCAN (IOFLUPANE I-123), a brain imaging agent used with SPECT to evaluate suspected parkinson…
-
FDA approval · 2015-09-10FDA Approved: NEUPRO — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for NEUPRO (rotigotine) submitted by UCB, Inc.
-
CLINICAL_TRIALS trial_result · 2015-09-07Clinical Trial Update: Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) [Phase 4]
Phase 4 clinical trial update for Apokyn aimed at improving morning akinesia in Parkinson's disease; status completed with results posted in…
-
CLINICAL_TRIALS research · 2015-09-07Clinical Trial Update: Assessment of Social-emotional Functioning in Neurological Diseases [NA]
This clinical trial update notes the completion of a study evaluating social-emotional functioning in multiple neurological diseases. Diseas…
-
CLINICAL_TRIALS trial_result · 2015-09-02Clinical Trial Update: Motor Cortex Stimulation for Parkinson's Disease [NA]
Completed clinical trial investigating motor cortex stimulation for Parkinson's disease.
-
CLINICAL_TRIALS research · 2015-08-26Clinical Trial Update: Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine [NA]
Clinical trial update on using midodrine to treat orthostatic intolerance in Parkinson's disease; the trial status is currently unknown.
-
CLINICAL_TRIALS trial_result · 2015-08-24Clinical Trial Update: Computer-based Cognitive Training for Parkinson Disease [NA]
The clinical trial evaluating computer-based cognitive training for Parkinson disease has completed.
-
CLINICAL_TRIALS trial_result · 2015-08-21Clinical Trial Update: Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone [Phase 1]
A Phase 1 study comparing two formulations of opicapone in Parkinson disease to characterize single-dose pharmacokinetics and relative bioav…
-
CLINICAL_TRIALS trial_result · 2015-08-20Clinical Trial Update: Effect of Rasagiline on BIA 9-1067 Pharmacokinetics [Phase 1]
Phase 1 study assessing the effect of rasagiline on the pharmacokinetics of BIA 9-1067 in Parkinson disease; results have been posted after …
-
CLINICAL_TRIALS trial_result · 2015-08-20Clinical Trial Update: Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic [Phase 1]
A Phase 1 study evaluated how BIA 9-1067 affects the pharmacokinetics of Levodopa in Parkinson's disease; the trial completed and results we…
-
CLINICAL_TRIALS trial_result · 2015-08-20Clinical Trial Update: Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide [Phase 1]
Phase 1 pharmacokinetic study assessing the effect of BIA 9-1067 on the PK of repaglinide in Parkinson disease; results have been posted.